Financial Survey: Fresh Tracks Therapeutics (NASDAQ:FRTX) vs. LENZ Therapeutics (NASDAQ:LENZ)

Fresh Tracks Therapeutics (NASDAQ:FRTX) and LENZ Therapeutics (NASDAQ:LENZ) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, dividends, earnings and institutional ownership.

Analyst Ratings

This is a summary of recent recommendations and price targets for Fresh Tracks Therapeutics and LENZ Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fresh Tracks Therapeutics	0	0	0	0	0.00
LENZ Therapeutics	0	0	6	1	3.14

LENZ Therapeutics has a consensus target price of $35.40, suggesting a potential upside of 34.40%. Given LENZ Therapeutics’ stronger consensus rating and higher probable upside, analysts plainly believe LENZ Therapeutics is more favorable than Fresh Tracks Therapeutics.

Risk and Volatility

Fresh Tracks Therapeutics has a beta of 0.51, meaning that its share price is 49% less volatile than the S&P 500. Comparatively, LENZ Therapeutics has a beta of 0.57, meaning that its share price is 43% less volatile than the S&P 500.

Earnings and Valuation

This table compares Fresh Tracks Therapeutics and LENZ Therapeutics”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fresh Tracks Therapeutics	$10.06 million	0.42	-$5.69 million	($1.41)	-0.50
LENZ Therapeutics	N/A	N/A	-$124.65 million	N/A	N/A

Fresh Tracks Therapeutics has higher revenue and earnings than LENZ Therapeutics.

Institutional & Insider Ownership

25.0% of Fresh Tracks Therapeutics shares are held by institutional investors. Comparatively, 54.3% of LENZ Therapeutics shares are held by institutional investors. 0.2% of Fresh Tracks Therapeutics shares are held by insiders. Comparatively, 38.4% of LENZ Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares Fresh Tracks Therapeutics and LENZ Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Fresh Tracks Therapeutics	N/A	N/A	N/A
LENZ Therapeutics	N/A	-58.48%	-55.50%

Summary

LENZ Therapeutics beats Fresh Tracks Therapeutics on 7 of the 11 factors compared between the two stocks.

About Fresh Tracks Therapeutics

Fresh Tracks Therapeutics, Inc. does not have significant operations. Previously, the company was engaged in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States. Fresh Tracks Therapeutics, Inc. was founded in 2009 and is headquartered in Boulder, Colorado.

About LENZ Therapeutics

LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.